Surface phenotype, T-cell proliferative responses to various β2GPI preparations, predicted β2GPI domain containing the epitope, and HLA class II restriction in 14 β2GPI-specific CD4+ T-cell clones
T-cell clones . | Surface phenotype . | Antigen-induced T-cell proliferative response . | Predicted β2GPI domain containing epitope . | HLA class II restriction* . | ||||
---|---|---|---|---|---|---|---|---|
Native β2GPI . | Reduced β2GPI . | GP1 . | GP2 . | GP3 . | ||||
Patient O.M. | ||||||||
OM2 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
OM3 | CD4+CD8− | − | + | + | − | − | I/II | HLA-DP |
OM7 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
OM8 | CD4+CD8− | − | − | − | − | + | V | HLA-DR |
Patient E.Y. | ||||||||
EY3 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
EY8 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
EY9 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
EY12 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
Patient K.S. | ||||||||
KS3 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
KS4 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
KS5 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
KS7 | CD4+CD8− | − | + | − | + | + | IV | HLA-DR |
KS8 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
KS10 | CD4+CD8− | − | + | − | + | + | IV | HLA-DR |
T-cell clones . | Surface phenotype . | Antigen-induced T-cell proliferative response . | Predicted β2GPI domain containing epitope . | HLA class II restriction* . | ||||
---|---|---|---|---|---|---|---|---|
Native β2GPI . | Reduced β2GPI . | GP1 . | GP2 . | GP3 . | ||||
Patient O.M. | ||||||||
OM2 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
OM3 | CD4+CD8− | − | + | + | − | − | I/II | HLA-DP |
OM7 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
OM8 | CD4+CD8− | − | − | − | − | + | V | HLA-DR |
Patient E.Y. | ||||||||
EY3 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
EY8 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
EY9 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
EY12 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
Patient K.S. | ||||||||
KS3 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
KS4 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
KS5 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
KS7 | CD4+CD8− | − | + | − | + | + | IV | HLA-DR |
KS8 | CD4+CD8− | − | + | − | − | + | V | HLA-DR |
KS10 | CD4+CD8− | − | + | − | + | + | IV | HLA-DR |
Determined based on blocking experiments using anti-HLA-DR, anti-HLA-DQ, and anti-HLA-DP mAbs.